Journal Pre-proof

Remdesivir as a possible therapeutic option for the COVID-19

Jaffar A. Al-Tawfiq, Ali H. Al-Homoud, Ziad A. Memish

PII: S1477-8939(20)30083-1
DOI: https://doi.org/10.1016/j.tmaid.2020.101615
Reference: TMAID 101615

To appear in: Travel Medicine and Infectious Disease

Received Date: 26 February 2020
Revised Date: 27 February 2020
Accepted Date: 3 March 2020

Please cite this article as: Al-Tawfiq JA, Al-Homoud AH, Memish ZA, Remdesivir as a possible therapeutic option for the COVID-19, Travel Medicine and Infectious Disease (2020), doi: https://doi.org/10.1016/j.tmaid.2020.101615.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Ltd.
Remdesivir as a Possible Therapeutic Option for the COVID-19

Jaffar A. Al-Tawfiq\textsuperscript{1,2,3*}, Ali H. Al-Homoud\textsuperscript{4}, and Ziad A. Memish, MD\textsuperscript{5,6,7}

\textsuperscript{1}Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia; \textsuperscript{2}Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; \textsuperscript{3}Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; \textsuperscript{4}Pharmacy Services Division, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia; \textsuperscript{5}Director Research Center, King Saud Medical City, Ministry of Health, \textsuperscript{6}Al-Faisal University, Riyadh, Saudi Arabia; \textsuperscript{7}Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA

Dr. Jaffar A. Al-Tawfiq*  
P.O. Box 76; Room A-428-2, Building 61, Dhahran Health Center,  
Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia.  
E-mail address: jaffar.tawfiq@jhah.com; jaltawfi@yahoo.com  
Tel: +966-13-870-3524; Fax: +966-13-870-3790

All authors have no conflicts of interest
To the editor,

In a recent review article, there were multiple preventive measures that were proposed for the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [1]. Since 2002, we had witnessed the emergence of three coronaviruses with a significant impact. These are the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), MERS-CoV and the SARS-CoV-2, the causative agent of COVID-19. SARS-CoV-2 emerged in Wuhan, China, in December 2019, and according to the World Health Organization (WHO), the global number of cases is 80239 confirmed as of February 25, 2020 [2]. However, there is no recommended therapy for any of these CoVs.

Remdesivir (with a development code GS-5734) is a broad-spectrum antiviral agent. This medication is an experimental drug and had not been licensed or approved at the time of writing this article. It was synthesized and developed by Gilead Sciences in 2017 as a treatment for Ebola virus infection. It is a monophosphoramidate prodrug and is an adenosine analog. Remdesivir is metabolized into its active form, GS-441524, that obscures viral RNA polymerase and evades proofreading by viral exonuclease, causing a decrease in viral RNA production. The antiviral mechanism for remdesivir is a delayed chain cessation of nascent viral RNA of Ebola virus. Remdesivir showed antiviral activity against multiple variants of Ebola virus in cell-based assays [3] as well as in a rhesus monkey model of Ebola virus disease, [4]. Remdesivir was given on a compassionate-use basis to a British nurse who survived Ebola virus disease when she relapsed nine months later in the United Kingdom with meningoencephalitis [5]. In a randomized controlled trial of Ebola Virus disease therapeutics, 673 participants received one of three monoclonal antibodies (Zmapp, mAb114 or REGN-EB3) or remdesivir [6]. However, the
study was stopped as an interim analysis found that individuals who received REGN-EB3 or mAb114 had greater survival than either ZMapp or remdesivir [6].

In-vitro studies showed that remdesivir can inhibit coronavirus such as SARS-CoV and MERS-CoV replication. In an in-vitro test utilizing epithelial cell cultures of a primary human airway, remdesivir was effective against bat CoVs, pre-pandemic bat CoVs, and circulating contemporary human CoV in primary human lung cells [7,8]. One study showed that remdesivir and interferon beta were superior to lopinavir, ritonavir and interferon beta both in vitro and in MERS-CoV mouse model [9].

With the emergence of the 2019-nCoV (COVID-19), we are in a need for an effective antiviral agent to be able to halt the current outbreak. It had been suggested that remdesivir might be an option for the therapy of the COVID-19 patients [10]. In a case report, remdisivir treatment with started intravenous on day 7 in a patient with 2019-nCoV (COVID-19) [11]. Given the broad-spectrum anti-CoV activity of remdesivir demonstrated in pre-clinical studies; a randomized, controlled, double blind clinical trial is planned to evaluate the efficacy and safety of remdesivir in hospitalized patients with mild or moderate 2019-nCoV respiratory disease [12].

This clinical trial has already involved 308 hospitalized adult patients with mild and moderate 2019-nCoV respiratory disease. The participants were randomized to either placebo or remdesivir 200 mg loading dose on day 1 followed by 100 mg iv once-daily as maintenance doses for 9 days. The primary outcome was defined as the Time to Clinical recovery (TTCR), up to 28 days [12]. TTCR is defined as the time (in hours) from initiation of study treatment (active or placebo) until normalization of fever, respiratory rate, and oxygen saturation, and alleviation of cough, sustained for at least 72 hours [12]. Another ongoing phase 3 randomized, double-blind, placebo-controlled, multicenter study is evaluating the efficacy and safety of remdesivir in
452 hospitalized adult patients with severe 2019-nCoV respiratory disease [13]. Any clinical impact of remdesivir on 2019-nCoV remains unknown, until we get final results of ongoing studies.

References:


